Transformed the scientific concept into a viable product pipeline and IP Portfolio. Recruited the team (functional experts CMC &regulatory and clinical) and external scientific and clinical advisors. Established budget and secured seed funds. Company selected by MassBio Accelerator & Launch Bio Big Pitch (Ist Round). Clinical trial start in 2021.

- Developed commercial strategy for gene-therapy for Parkinson
- Payor research and insight for market access strategy and optimized reimbursement of Gene-therapy
- Commercial insight into an early stage gene-therapy for rare disease

Advised leadership of BioPharma, Device and AI Diagnostic companies regarding portfolio, programs, business development & new product strategy including: Analysis of strategic options, value-story, deal-structure, pricing, reimbursement and commercialization. Representative engagements include:
- Commercial strategy (Sales, marketing, pricing, reimbursement, contracting) for new CNS product launch.
- Market shaping and Omni-channel marketing strategy for a rare disease company.

Managed P&L for the US-Rx business unit (200+ FTE) that delivered 63% of company’s global revenue. Recruited and built new teams for patients and HCP marketing, market access, contracting, trade and marketing. Developed one, five and ten-year strategic plans and budget for current products and clinical pipeline programs.

- Launched 6 new brands & repositioned two mature brands turning decline into steady growth
- Doubled prescriptions (Rx) in four years: ~ 9.49M (Rx) in 2009 to ~ 20M Rx in 2014.
- Delivered CAGR of 17%+ over 4.5 years, leading India business to become fastest-growing UCB affiliate and one of the three fastest-growing multi-national companies in India.

Recruited for developing marketing strategy and execution for launch of FluMistTM vaccine in Europe (FluenzTM), Latin America, Asia and Middle East. Led cross-functional, global 30-member team responsible for all aspects of launch—clinical development planning, regulatory approval with right label, manufacturing, supply/distribution, marketing, market access and contracts with health ministries.

Promoted to lead matrixed team and marketing strategy for influenza portfolio comprised of three existing and four pipeline products for seasonal and pandemic flu, including vaccines and antiviral drugs.
- Launched GSK Influenza KOL Academy in collaboration with the clinical team. Developed scientific and healthcare professional education plan; gathered input on TPP and program strategy